Medical Condition News

RSS

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Rogue super-activated neutrophils may cause organ damage in parts unconnected to injury

A study from scientists at Queen Mary, University of London, sheds new light on why people who experience serious trauma or go through major surgery, can suffer organ damage in parts of the body which are seemingly unconnected to the injury.

27 Jun 2011

FDA responds to EpiCept Ceplene SPA

EpiCept Corporation today announced that it has received initial written responses from the U.S. Food and Drug Administration regarding the Company's application for a Special Protocol Assessment (SPA) of the Ceplene (histamine dihydrochloride) Phase III protocol.

27 Jun 2011

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

27 Jun 2011

Chaos in biochemical alterations of cancer cells

Using the latest gene sequencing tools to examine so-called epigenetic influences on the DNA makeup of colon cancer, a Johns Hopkins team says its results suggest cancer treatment might eventually be more tolerable and successful if therapies could focus on helping cancer cells get back to normal in addition to strategies for killing them.

27 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Endo recalls two lots of Endocet Tablets

Endo Pharmaceuticals today issued a voluntary nationwide consumer level recall of Endocet (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg 100 count bottles, NDC 60951-712-70, Lot # 402415NV and #402426NV.

27 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

Spectranetics initiates enrollment in EXCITE clinical trial against femoropopliteal IRS

Spectranetics Corporation today announces the first patient enrollment in the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

BD receives CEO Cancer Gold Standard accreditation

BD has received CEO Cancer Gold Standard accreditation, recognizing the company's commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for its own employees and their covered family members.

From BD (Becton, Dickinson and Company) 27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

Ivantis announced today at the World Glaucoma Congress in Paris that it has received $17 MM in funding from New Enterprise Associates (NEA) and Delphi Ventures.

27 Jun 2011

STAAR Surgical completes first procedures to implant Visian ICL V4c design

STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive refractive lenses that go inside the eye, today announced the completion of the first procedures to implant its recently CE Mark-approved Visian Implantable Collamer Lens V4c design.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

While genetic inheritance is known to play a role in the multifactorial development of most diseases of the heart, there are also a number of clearly diagnosed cardiac conditions which owe their development to quite specific genetic abnormalities. When these genetic disorders affect the integrity of the heart's muscle they are known as a "cardiomyopathy"; when the disorder affects the heart's "excitability", it is known as a "channelopathy".

27 Jun 2011

Study finds increase in life expectancy for people with type 1 diabetes

The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.

27 Jun 2011

Medical Condition News

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

Genentech, FORMA enter structurally innovative agreement for small molecule cancer program

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Rogue super-activated neutrophils may cause organ damage in parts unconnected to injury

FDA responds to EpiCept Ceplene SPA

Redefinition of cardiac hypertrophy term needed

Chaos in biochemical alterations of cancer cells

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Endo recalls two lots of Endocet Tablets

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Spectranetics initiates enrollment in EXCITE clinical trial against femoropopliteal IRS

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BD receives CEO Cancer Gold Standard accreditation

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Ivantis receives $17 MM NEA, Delphi Ventures funds to expand Hydrus device clinical activities

STAAR Surgical completes first procedures to implant Visian ICL V4c design

Positive results from Stealth's Bendavia Phase I renal impairment study

New guide indicates when and how genetic testing is useful for inherited cardiac conditions

Study finds increase in life expectancy for people with type 1 diabetes

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News